Is LH stock overvalued right now?

LH is trading near our fair value estimate of $282.51, within a normal valuation band.

What is LH fair value based on current fundamentals?

Our fair value estimate for LH is $282.51, derived from discounted cash flow, dividend discount, and relative valuation multiples. The estimate assumes a discount rate of 9.0% and terminal growth of 2.5%.

How risky is LH compared with other stocks?

LH carries a beta of 0.85 is near market average. Investors should weigh macro exposure against their own risk tolerance.

Latest trailing metrics show revenue growth of 5.8% and earnings growth of 28.2%. Profit margins are 7.0%.

What do analysts think about LH?

Analyst consensus target is $343.31, implying 6.0% upside. The street recommendation is "buy".

Does LH pay a dividend?

Yes. LH currently offers a dividend yield of 0.9%.

What could change the investment case for LH?

Key catalysts include Healthcare sector dynamics, interest rate shifts, and company-specific earnings surprises. Monitor macro risk scores and analyst estimate revisions for early signals.

HealthcareUpdated·Data: Yahoo Finance, SEC EDGAR·Data delayed ~5 min

Breakdown LH Breakout Candidate Win Rate result Hold Signal

NYQ · Healthcare · Diagnostics & Research

$323.97

+8.66 (+2.75%)

Stock valuation guide Macro risk explained guide

About the Author

Phasakorn Traklang (Peach) — Founder

Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.

Connect on LinkedIn

Investment Disclaimer: QuantSoar is for informational purposes only. We do not provide personalized investment advice. Always conduct your own research or consult a financial advisor. SEC

Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.